









Markets
/
Stocks
/
nasdaq-bgm
/

BGM Group Ltd

BGM

9.635USD

0.000

Close 11/03, 16:00（ET）Quotes delayed by 15 min

947.07MMarket Cap

--P/E TTM



BGM Group Ltd

9.635

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BGM Group Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very low. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BGM Group Ltd's Score

Industry at a Glance

Industry Ranking

138 / 173

Overall Ranking

593 / 4682

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

BGM Group Ltd Highlights

StrengthsRisks

BGM Group Ltd, formerly Qilian International Holding Group Ltd, is a company mainly engaged in the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives (TCMD) product, heparin product, sausage casings and fertilizers. The Company operates through three segments: Oxytetracycline & Licorice Products and TCMD segment, Fertilizer segment and Heparin Products and Sausage Casing segment. The Company's main brand is Qilian Shan. The Company principally operates its businesses within the domestic market.

Growing

The company is in a growing phase, with the latest annual income totaling USD 25.10M.

Overvalued

The company’s latest PE is -32.82, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 132.27K shares, increasing 18.83% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 29.97K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Pharmaceuticals industry's average is 7.77. Its latest quarterly revenue reached 12.54M, representing a year-over-year decrease of 27.57%, while its net profit experienced a year-over-year decrease of 77.56%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

BGM Group Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 5.15, which is lower than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -32.82, which is -22.46% below the recent high of -25.45 and -98.36% above the recent low of -65.11.

Score

Industry at a Glance

Previous score

5.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 138/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.27, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 10.41 and the support level at 8.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.34

Change

-0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Neutral

RSI(14)

53.188

Neutral

STOCH(KDJ)(9,3,3)

44.199

Buy

ATR(14)

0.399

Low Volatility

CCI(14)

167.978

Buy

Williams %R

42.273

Buy

TRIX(12,20)

-0.048

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

9.373

Buy

MA10

9.428

Buy

MA20

9.459

Buy

MA50

9.068

Buy

MA100

9.503

Buy

MA200

10.266

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 0.09%, representing a quarter-over-quarter decrease of 99.88%. The largest institutional shareholder is James Simons, holding a total of 29.97K shares, representing 0.02% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Success Myth Ltd

38.17M

Feng (Zhuojun)

24.46M

AIFU Inc

16.53M

-76.39%

Lou (Zefei)

8.79M

Xin (Zhanchang)

2.40M

Ahanzhai Development Co., Ltd

367.80K

Geode Capital Management, L.L.C.

38.91K

+722.86%

Renaissance Technologies LLC

Star Investors

29.97K

+125.60%

Marshall Wace LLP

20.63K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.